Calliditas rises on positive EMA feedback for genetic disease drug

Calliditas Therapeutics AB

05/10/2023 16:35

**  U.S.-listed shares of Sweden-based drug developer
Calliditas Therapeutics AB  CALTX.ST   CALT.O  rise 4.5% to
$18.5 
    ** Says the European Medicines Agency has issued a positive
opinion on CALT's application to  grant "orphan drug" status to
its experimental drug to treat Alport syndrome    
    ** Alport syndrome is a genetic condition characterized by
kidney disease, hearing loss and eye abnormalities
    ** CALT plans to begin a mid-stage trial testing the drug,
setanaxib, in about 20 patients in Q4 2023   
     ** EMA defines orphan drugs as medicinal products for the
diagnosis, prevention or treatment of a rare, life-threatening
or chronically debilitating condition
    ** Including session gains, U.S.-listed shares of CALT up
~11.4% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))